Alle Studien
RekrutierungPHASE1INTERVENTIONELL

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

This research is looking at a new medicine called ALN-5288 for individuals living with Alzheimer's disease. The main goal is to find out if the medicine is safe and well-tolerated when given directly into the fluid around the brain and spinal cord. Researchers will also be observing how the medicine works in the body and if it has any effects on the disease itself. To understand this properly, some participants will receive the active study medicine, while others will be given a placebo, which looks like the medicine but contains no active drug. This helps scientists compare the effects fairly. Participants will be aged between 40 and 80 and have a diagnosis of Alzheimer's.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE1
Sponsor
Alnylam Pharmaceuticals
Einschreibeziel
50
Starten
15. Okt 2025
Geschätzte Fertigstellung
06 Mar 2030

Worum geht es in dieser Studie?

This study is a research project designed to learn more about a new medicine called ALN-5288 for people with Alzheimer's disease. Alzheimer's is a condition that affects memory, thinking, and daily activities. The medicine is given into the fluid that surrounds your brain and spinal cord, similar to an injection you might get for a spinal tap.

The main aim of this study is to check if ALN-5288 is safe and if your body can handle it well. We also want to understand how your body processes the medicine and what effects it might have on the disease. By taking part, you would be helping doctors and scientists learn more about new ways to treat Alzheimer's, which could help many other people in the future.

It's important to remember that this is a very early-stage study (called Phase 1). This means it's one of the first times this medicine is being tested in humans. Because of this, we don't yet know if the medicine will be effective, but understanding its safety is a crucial first step.

Wichtige Erkenntnisse

  • This study is for a new medicine (ALN-5288) for Alzheimer's disease.
  • The main goal is to check for safety and how the medicine works in the body.
  • Participants will receive the medicine or a placebo via spinal injection.
  • You must be 40-80 years old with an Alzheimer's diagnosis to join.
  • Eine enge medizinische Überwachung wird während der gesamten Studie bereitgestellt.
  • Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.

Wer könnte berechtigt sein?

To join this study, you would generally need to be between 40 and 80 years old and have a diagnosis of Alzheimer's disease. This diagnosis needs to be supported by special tests, like certain brain scans or checks of your spinal fluid, and confirmed within the last 7 years. You should also have mild memory problems or dementia linked to Alzheimer's.

There are also some important reasons why someone might not be able to join. For example, if your memory problems are caused by a different kind of dementia, or if you have certain health conditions like severe high blood pressure, uncontrolled seizures, or particular heart, liver, or kidney problems. You also wouldn't be able to join if you have certain infections like HIV or hepatitis.

Finally, if you have other serious mental health conditions that aren't well controlled, or if you have problems with your brain or spine that would make injections into that area difficult, you would not be able to participate. The study team will check all these things carefully to make sure it's safe for you to take part.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you between 40 and 80 years old?
  2. Do you have a diagnosis of Alzheimer's disease confirmed by special tests?
  3. Do you have mild memory problems or dementia related to Alzheimer's?
  4. Do you have any serious heart, liver, or kidney problems?
  5. Do you have uncontrolled high blood pressure or seizures?
  6. Do you have certain infections like HIV or hepatitis?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you would receive either the new study medicine, ALN-5288, or a placebo (a dummy medicine with no active drug). This will be given through an injection into the fluid around your spinal cord. The study involves regular visits to the clinic for medical checks, further injections, and to monitor your health and any effects of the medicine. You will have blood tests and other examinations.

The exact number of visits and the full length of your participation would be explained in detail by the study team. They will monitor your health closely throughout the study period. It's important to know that you wouldn't necessarily know whether you are receiving the active drug or the placebo, as this helps ensure the results are accurate and unbiased.

Potenzielle Risiken und Vorteile

Potential benefits of taking part could include gaining access to a new experimental medicine for Alzheimer's disease that isn't yet available generally. You would also receive close medical attention and monitoring throughout the study. However, because this is an early-stage study, it's not known if ALN-5288 will help your Alzheimer's symptoms. Potential risks could include side effects from the medicine itself, or discomfort and risks associated with the injections into your spinal fluid. As with all medical procedures, complications can occur, although the study team will take every precaution. You will receive a full explanation of all known and potential risks before you decide to participate, and you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Standorte (13)

  • Clinical Trial Site
    Verifizierte Postleitzahl
    Montreal, Kanada· Rekrutierung
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Ottawa, Kanada· Rekrutierung
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Toronto, Kanada· Rekrutierung
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Toronto, Kanada· Noch nicht rekrutiert
  • Clinical Trial Site
    Verifizierte Postleitzahl
    's-Hertogenbosch, Netherlands· Rekrutierung
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Amsterdam, Niederlande· Rekrutierung
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Barcelona, Spanien· Noch nicht rekrutiert
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Madrid, Spanien· Rekrutierung
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Sant Cugat del Vallès, Spain· Noch nicht rekrutiert
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Glasgow, Vereinigtes Königreich· Rekrutierung
  • Clinical Trial Site
    Verifizierte Postleitzahl
    London, Vereinigtes Königreich· Rekrutierung
  • Clinical Trial Site
    Verifizierte Postleitzahl
    Sheffield, United Kingdom· Rekrutierung

Häufige Fragen

What is ALN-5288?

ALN-5288 is a new medicine being tested for Alzheimer's disease. We are trying to find out if it is safe and how it works in the body.

Wie wird das Medikament verabreicht?

The medicine will be given through an injection directly into the fluid around your spinal cord, similar to a spinal tap.

Will I get the real medicine or a dummy medicine?

Some people in the study will get the active medicine, and others will get a placebo (a dummy medicine). This helps us compare the effects fairly, and you won't know which one you are receiving.

Wie lange muss ich an der Studie teilnehmen?

The total duration of your participation will be explained by the study team, but it will involve several visits over a period of time.

Kann ich die Studie jederzeit verlassen?

Yes, you are free to leave the study at any time, for any reason, without it affecting your regular medical care.

Wie Sie mehr erfahren können

Clinical Trial Information Line

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study to Evaluate ALN-5288 in Patients With Alzheimer's Di… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.